Pfizer Recalls Painkiller Over Stability Issue

Pfizer Inc. is recalling about 100,000 bottles of popular painkiller Embeda after a routine test showed it didn’t meet stability standards. Levels of one of the ingredients found in the drug were above what was expected.

A statement released by Pfizer said that the recalled drug “is unlikely to pose a safety risk to patients using Embeda as prescribed,” and patients can continue taking supplies of the drug they already have. All dosage forms of Embeda extended-release capsules CII are subject to recall.”

Pfizer also cautioned that patients check with doctors before starting an alternate course of treatment. Embeda first appeared on the market in 2009 as the first approved opioid pain product with design features intended to discourage misuse and abuse. Its effects are neutralized when tampered with by crushing or chewing. Pfizer acquired the drug after purchasing King Pharmaceuticals in January for $3.3 billion.

Other Pfizer recalls in recent months have included batches of the Lipitor cholesterol-lowering pill and Caverject anti-impotence shot.

No related posts.